2026-10-12T15:37:18Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33770791 2026-09-15T04:27:47Z category_696 portal_316 item_type_3 month_year_09_2026

Supplementary file 2_Allogeneic hematopoietic stem cell transplantation is associated with improved survival compared with chemotherapy in patients with acute myeloid leukemia harboring favorable-risk genetic features at initial diagnosis: a single-center retrospective study.pdf Rujiao Dong (15325303) Lihua Wu (755792) Chunling Zhao (3389945) Xianling Chen (732652) Xiaohong Yuan (430571) Zhijuan Zhu (11644585) Xiaofan Li (569074) Nainong Li (11644591) Genetic Immunology acute myeloid leukemia allogeneic hematopoietic stem cell transplantation chemotherapy favorable-risk genetic features at initial diagnosis measurable residual disease relapsed/refractory leukemia Background<p>Acute myeloid leukemia (AML) harboring favorable-risk genetic features at initial diagnosis (FR-AML) commonly achieves remission after chemotherapy, but the optimal post-remission strategy remains controversial. This study compared allogeneic hematopoietic stem cell transplantation (allo-HSCT) with chemotherapy and explored prognostic factors.</p>Methods<p>We retrospectively analyzed 190 patients with FR-AML treated at Fujian Medical University Union Hospital between 2012 and 2022. Patients were stratified into the chemotherapy (n = 118) and allo-HSCT (n = 72) groups according to their post-induction treatment. Survival outcomes, including overall survival (OS), leukemia-free survival (LFS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM), were assessed using Kaplan–Meier and competing-risk analyses. Multivariate Cox regression identified independent prognostic factors.</p>Results<p>At 3 years, the allo-HSCT group had higher OS (86.0% vs. 61.3%, P < 0.0001) and LFS (59.2% vs. 49.3%, P = 0.039) than the chemotherapy group, with lower CIR (3.8% vs. 33.6%, P < 0.0001). Stratified analyses showed that allo-HSCT was associated with improved 3-year OS compared with chemotherapy alone in CR1-AML and R/R AML patients. In CR1-AML, the 3-year OS was 92.8% versus 73.6% (P = 0.0099), whereas in R/R AML, it was 73.5% versus 26.6% (P = 0.00015). By age, outcomes were comparable among patients aged <20 years, whereas allo-HSCT was associated with better survival in those aged 20–60 years. Among 66 transplanted patients with measurable residual disease (MRD) data, 3-year OS did not differ significantly between MRD-positive and MRD-negative groups (86.0% vs. 85.6%, P = 0.35).</p>Conclusions<p>Allo-HSCT was associated with improved survival and reduced relapse in FR-AML. This benefit extended beyond patients transplanted in CR1 to those who later develop R/R disease, in whom salvage allo-HSCT confers a marked survival advantage over chemotherapy. Deferred transplantation may remain feasible for selected patients when a suitable donor is available. Prospective studies are warranted to validate these findings and optimize post-remission treatment strategies in this population.</p> 2026-09-15T04:27:47Z Dataset Dataset 10.3389/fimmu.2026.1825310.s001 https://figshare.com/articles/dataset/Supplementary_file_2_Allogeneic_hematopoietic_stem_cell_transplantation_is_associated_with_improved_survival_compared_with_chemotherapy_in_patients_with_acute_myeloid_leukemia_harboring_favorable-risk_genetic_features_at_initial_diagnosis_a/33770791 CC BY 4.0